Table 1 Characteristics of patient
From: Tuberculosis presenting as immune thrombocytopenic purpura
Day | Hb (g/dl) | Hct (%) | WBC (×109) | Plt (×109) | Treatment |
|---|---|---|---|---|---|
1 | 11.2 | 36 | 25.1 | 7.6 | Anti-tbc drugs + IVIg |
2 | 8 | 25 | 23.1 | 9.6 | Anti-tbc drugs + IVIg+Pred+1 RBC Susp |
3 | 8.1 | 25 | 22.7 | 17.7 | Anti-tbc drugs+ Pred+ 2 RBC Susp |
4 | 10.3 | 33 | 20.6 | 15.1 | Anti-tbc drugs+ Pred |
5 | 8.6 | 27 | 24.5 | 12.3 | Anti-tbc drugs+ Pred+ 1 RBC Susp |
6 | 8.2 | 24 | 25.4 | 4.0 | Anti-tbc drugs + Pred + 2 RBC Susp |
7 | 10.1 | 29 | 20.6 | 4.7 | Anti-tbc drugs+ Pred |
8 | 10.5 | 32 | 17.7 | 20.2 | Anti-tbc drugs+ Pred |
9 | 9.9 | 31 | 15.8 | 36.6 | Anti-tbc drugs+ Pred |
10 | 10.3 | 33 | 18 | 59 | Anti-tbc drugs+ Pred |
11 | 9.4 | 28 | 14 | 100 | Anti-tbc drugs+ Pred |
12 | 9.7 | 28 | 18.1 | 187 | Anti-tbc drugs+ Pred |
13 | 9.1 | 26 | 15.2 | 324 | Anti-tbc drugs+ Pred |
14 | 9.6 | 28 | 17 | 310 | Anti-tbc drugs |
45 | 12.3 | 37 | 15.5 | 304 | Anti-tbc drugs |
90 | 14 | 43 | 11 | 300 | Anti-tbc drugs |